Gastroesophageal reflux disease in a comorbid patient, refractory to proton pump inhibitors. How can we help?

Background. Gastroesophageal reflux disease is a multifactorial disease that is quite common in clinical practice. High prevalence, a clear trend towards increasing incidence not only in Russia, but also in all countries of the world, chronic relapsing course and significant impact on the quality of life of patients, the complexity of managing patients with gastroesophageal reflux disease, especially in comorbid patients, often distinguish it from other types of organ pathologies digestion. A significant contribution to the development of gastroesophageal reflux disease in a comorbid patient is made by obesity, hiatal hernia, duodenogastroesophageal reflux, etc.

Results. First-line therapy for gastroesophageal reflux disease is proton pump inhibitors. Often, it is in a comorbid patient that an incomplete response to roton pump inhibitor monotherapy may occur, when the clinician faces the difficult problem of diagnosing the causes of nonresponse, as well as approaches to the treatment of refractory gastroesophageal reflux disease. An integrated approach to the treatment of gastroesophageal reflux disease in a comorbid patient allows for relief of the symptoms of the disease. At the same time, it is important to take into account the risks of drug-drug interactions of prescribed drugs, given the fact that comorbid patients initially receive a considerable number of medications for other diseases. In this regard, an effective approach to the treatment of gastroesophageal reflux disease may be the administration of alginic acid in combination with proton pump inhibitors. Аlginic acid, being a universal antireflux drug, has sorption properties, which is important for mixed reflux. In addition, the use of alginates is compatible with proton pump inhibitors. The alginic acid containing drug, due to its composition and mechanism of action, is effective and safe in comorbid patients.

1. Isakov V. A., Morozov S. V., Stavraki E. S., Komarov R. M. Analysis of heartburn prevalence: a national epidemiological study of the adult urban population (ARIADNA). Eksperimental'naya i klinicheskaya gastroenterologiya. 2008; 1: 20-29. (In Russ.)

2. Lazebnik L.B., Masharova A.A., Bordin D. S., Vasiliev Yu. V., Tkachenko E. I., et al. Results of multicentre study "Epidemiology of Gastroesophageal Reflux Disease in Russia" ("MEGRE"). Therapeuticheskiy archiv. 2011; 1: 45-50. (In Russ.)

3. Gaddam S., Sharma P. Shedding light on the epidemiology of gastroesophageal reflux disease in India – a big step forward. Indian J Gastroenterol. 2011; 30 (3): 105-107. URL: http://medind.nic.in/ica/t11/i3/icat11i3p105.pdf.

4. Salis G. Systematic review: Epidemiology of gastroesophageal reflux disease in Latin America. Acta Gastroenterol Latinoam. 2011; 41 (1): 60-69. URL: http://www.ncbi.nlm.nih.gov/pubmed/21539070.

5. Lim L. G., Ho K. Y. Gastroesophageal reflux disease at the turn of millennium. World Journal of Gastroenterology. 2003; 9 (10): 2135-2136.

6. Balabantsev A. G. G., Bogdanov V. V., Lukashik N. V. Gastroesophageal reflux disease. Clinic, diagnostics, peculiarities of manifestations on the side of ENT-organs. 19.09.2007. URL: http:// consilium.com.ua/profile/225/stuff/id-1146/. (In Russ.)

7. Oganov R. G., Denisov I. N., Simanenkov V. I., Bakulin I. G., Bakulina N. V., Boldueva S. A., Barbarash O. N., Garganeeva N. P., Doshchitsin V. L., Drapkina O. M., Dudinskaya E. N., Kotovskaya Yu. V., Lila A. M., Mamedov M. N., Mardanov B. U., Miller O. N., Petrova M. M., Pozdnyakov Yu. M., Runikhina N. K., Sayganov S. A., Tarasov A. V., Tkacheva O. N., Urinsky A.M., Shalnova S.A. Comorbidities in clinical practice. Clinical guidelines. Kardiovaskulyarnaya terapiya I profilaktika. 2017; 16 (6): 5-56. (In Russ.) https://doi.org/10.15829/1728-8800-2017-6-5-56

8. Juniarta P. M., Wibawa I. D. N. Drug-induced Esophagitis. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2019; 20 (2):104.

9. Bahar A., Syam A. F., Manan C. The Diagnostic and Management of Drug Induced Esophagitis. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy. 2002; 3 (3): 86-90.

10. Osadchuk A. M., Davydkin I. L., Gricenko T. A., Osadchuk M. A. Gastroesophageal reflux disease and esophagitis associated with the use of drugs: the modern state of the problem. Terapevticheskii arkhiv. 2019; 91 (8): 135-140. (In Russ.) DOI: 10.26442/00403660.2019.08.000228

11. Zografos G. N., Georgiadou D., Thomas D. Druginduced esophagitis. Diseases of the Esophagus. 2009; 22 (8): 633-637.https://doi.org/10.1111/j.1442-2050.2009.00972.x.

12. Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophagogastroenterocolopathies induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Eksperimentalnaya i klinicheskaya gastroenterologiya. 2018; (3): 4-18. (In Russ.)

13. Bigard M., Pelletier A. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol Clin Biol. 2004; 3: 58-61.

14. Arutyunov A. G., Burkov S. G. Gastroesophageal reflux disease in elderly and elderly patients. G. Gastroesophageal reflux disease in elderly and senile patients. Klinicheskie perspektivy gastroenterologii, hepatologii. 2005; 1: 31-38. (In Russ.)

15. Jansson C., Nordenstedt H., Wallander M. A., et al. Severe symptoms of gastro-oesophageal reflux disease are associated with cardiovascular disease and other gastrointestinal symptoms, but not diabetes: a population-based study. Alimentary Pharmacology & Therapeutics. 2008; 27 (1): 58-65.

16. Hampel H., Abraham N. S., El Serag H. B., et al. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of Internal Medicine. 2005; 143: 199-211.

17. Côté-Daigneault J., Leclerc P., Joubert J., Bouin M. High prevalence of esophageal dysmotility in asymptomatic obese patients. Can J Gastroenterol Hepatol. 2014; 28 (6): 311-314. DOI: 10.1155/2014/960520.

18. Popescu A. L., Costache R. S., Costache D. O., Balaban V. D., Jinga M., Ionita-Radu F., Caruntu A., Fierbinteanu-Braticevici C. Manometric changes of the esophagus in morbidly obese patients. Exp Ther Med. 2021; 21 (6): 604. DOI: 10.3892/etm.2021.10036.

19. Jackson S. J., Leahy F. E., McGowan A. A., Bluck L. J., Coward W. A., Jebb S. A. Delayed gastric emptying in the obese: an assessment using the non-invasive (13)C-octanoic acid breath test. Diabetes Obes Metab. 2004; 6 (4): 264-270. DOI: 10.1111/j.1462-8902.2004.0344.x.

20. Miron I., Dumitrascu D. L. Gastrointestinal motility disorders in obesity. Acta Endocrinol (Buchar). 2019; 15 (4): 497-504. DOI: 10.4183/aeb.2019.497.

21. Ivashkin V. T., Maev I. V., Trukhmanov A. S., Lapina T. L., Storonova O. A., Zayratyants O. V., Dronova O. B., Kucheryavyy Yu. A., Pirogov S. S., Sayfutdinov R. G., Uspenskiy Yu. P., Sheptulin A .A., Andreev D. N., Rumyantseva D. E. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2020; 30 (4): 70-97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97

22. Romagnoli R., Collard J.-M., Serra A.-M., et al. Is the DGR Bilitec® profile different in GERD patients with and without Barrett’s esophagus? In: Giuli R., Scarpignato C., Collard J.-M., et al. Eds. The Duodenogastroesophageal reflux. Paris: John Libbey, 2006. Р. 445-449.

23. Mabrut J. Y., Romagnoli R., Collard J.-M., et al. Familial adenomatous polyposis predisposes to pathological exposure of the stomach to bilirubin. Surgery. 2006; 140: 818-823.

24. Bernstein H., Bernstein C., Payne C. M., Dvorakova K., Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005; 589: 47-65.

25. Chen J. W., Vela М. F., Peterson К. А., Carlson D. A. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review. Clinical Gastroenterology and Hepatology. 2023; 21: 1414- 1421. https://doi.org/10.1016/j.cgh.2023.01.040.

26. Weijenborg, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012; 24 (8): 747-757.

27. Inadomi J. M., McIntyre L., Bernard L., et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am. J. Gastroenterol. 2003; 98: 1940-1944.

28. Zerbib F., Bredenoord A. J., Fass R., Kahrilas P. J., Roman S., Savarino E., Sifrim D., Vaezi M., Yadlapati R., Gyawali C. P. ESNM/ ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease. Neurogastroenterol Motil. 2021; 33 (4): e14075. DOI: 10.1111/nmo.14075.

29. Subramanian Ch. R., Triadafilopoulos G. Refractory gastroesophageal reflux disease. Gastroenterology Report. 2015; 3: 41-53. DOI: 10.1093/gastro/gou061.

30. De Bortoli N., Tolone S., Frazzoni M., et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018; 31 (6): 639-648. DOI: 10.20524/aog.2018.0314.

31. Osadchuk M. A., Osadchuk M. M. Crossing syndrome of functional dyspepsia, gastroesophageal reflux disease and irritable bowel syndrome: optimisation of therapy. RMZh. 2015; 28: 1690-1692. (In Russ.)

32. Tytgat G. N., McColl K., Tack J., Holtmann G., Hunt R. H., Malfertheiner P., et al. New algorithm for the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2008; 27: 249-256. DOI: 10.1111/j.1365-2036.2007.03565.x.

33. Pandolfino J. E., Vela M. F. Esophageal-reflux monitoring. Gastrointest Endosc. 2009; 69: 917-30. DOI: 10.1016/j.gie.2008.09.022.

34. Sablin O.A., Ilchishina T.A. Problems of nociception in gastroesophageal reflux disease: diagnostics and treatment of irritated oesophagus. Terapevticheskii arkhiv. 2018; 90 (8): 118-124. (In Russ.) DOI: 10.26442/terarkh2018908118-124

35. Xu X. R., Li Z. S., Zou D. W., Xu G. M., Ye. P., Sun Z. X., Wang Q., Zeng Y. J. Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Can J Gastroenterol. 2006; 20 (2): 91-94. DOI: 10.1155/2006/498142.

36. Sheptulin A. A., Kurbatova A. A., Baranov S. A. Modern options of prokinetics in gastroesophageal reflux disease treatment. Ros. zhurn. gastroenterol. gepatol. koloproktol. 2018; 28 (1): 71-77. (In Russ.) DOI: 10.22416/1382-4376-2018-28-1-71-77.

37. Bischoff S. C., Barazzoni R., Busetto L., et al. European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline. Clin Nutr. 2022; 41 (10): 2364-2405. DOI: 10.1016/j.clnu.2022.07.003.

38. Pakhomova I. G., Uspensky Y. P., Pavlova E. Y. Prospects for the use of the drug "Geviscon fort" in the treatment of GERD and NSAID-induced oesophageal lesions. Consilium Medicum. Gastroenterologia (Pril.). 2011; 2: 13-17. (In Russ.)

39. Kwiatek M. A., Roman S., Fareeduddin A., Pandolfino J. E., Kahrilas P. J. An alginateantacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011; 34: 59-66. DOI: 10.1111/j.1365-2036.2011.04678.x.

40. Thomas E., Wade A., Crawford G., Jenner B., Levinson N., Wilkinson J. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) – a doubleblind, placebo-controlled, pilot study in gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2014; 39: 595-602. DOI: 10.1111/apt.12640.

41. Bordin D. S., Firsova L. D. Alginate test in the diagnosis of endoscopically negative form of gastroesophageal reflux disease. RMZh. 2012; 35: 1689. (In Russ.)

42. Instructions for use Gaviscon® Double Action from 16.08.2016. Pharmacotherapeutic group: means of treatment of reflux esophagitis. Registration certificate: LP-001624. (In Russ.)